94 Solaris Avenue
Camana Bay
Grand Cayman KY1-1108
Cayman Islands
345 949 4123
https://www.beigene.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10,600
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. John V. Oyler | Co-Founder, Executive Chairman & CEO | 2.05M | N/A | 1968 |
Dr. Xiaobin Wu Ph.D. | President & COO | 1.69M | N/A | 1962 |
Dr. Xiaodong Wang Ph.D. | Co- Chairman of Scientific Advisory Board & Non-Executive Director Co-Founder | 250k | N/A | 1963 |
Ms. Julia Wang | CFO & Principal Financial Officer | 964.2k | N/A | 1972 |
Mr. Wang Lai Ph.D. | Global Head of R&D | 996.92k | 9.13M | 1977 |
Mr. Titus B. Ball | VP & Chief Accounting Officer | N/A | N/A | 1973 |
Ms. Liza Heapes | Head of Investor Relations | N/A | N/A | N/A |
Mr. Chan Lee | General Counsel & Senior VP | N/A | N/A | N/A |
Mr. Yang Ji | Chief Compliance Officer | N/A | N/A | N/A |
Dr. Yan Qi | Senior VP & Head of Public Affairs - Greater China | N/A | N/A | N/A |
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
BeiGene, Ltd.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 6; Compensation: 10.